Video

Prostate Cancer: To Treat or Not to Treat

We've come a long way in determining which patients with prostate cancer to treat, but there is still more work that needs to be done.

Prostate cancer is a complicated disease, and while understanding of it has improved in recent years, knowledge gaps still need to be addressed, according to Howard Soule, Ph.D., chief science officer at the Prostate Cancer Foundation.

Soule noted there is a need for better predictors to determine who should be treated and who should be observed with active surveillance. Now, most patients with low-grade disease undergo active surveillance, but, Soule adds, that does not mean that they are not doing anything. In fact, they frequently visit their urologist and have biopsies so that if the disease does progress to the point where it needs to be treated, it can be done in the earliest stages. With active surveillance, men can go years — or potentially for the rest of their lives – without undergoing prostate cancer treatment.

Related Videos
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with brown and grey hair.
Image of man with grey hair.
Image of bald man in suit.